Eli Lilly (LLY) is going after two more drug compounders that continue to make and sell copies of its weight loss drug despite a March court order against it, multiple media outlets reported Tuesday.

The company's latest lawsuits were filed against Strive Pharmacy and Empower Clinic Services, Reuters reported. The company is demanding that compounders stop selling products with tirzepatide, the active ingredient in its weight loss and diabetes drugs Zepbound and Mounjaro.

Lilly had filed lawsuits against over two dozen medical spas, wellness centers, and compounding pharmacies, according to the report.

The company also plans to send around 50 cease-and-desist letters asking compounders and telehealth companies to confirm by April 8 that they have stopped manufacturing and selling all forms of compounded tirzepatide, Bloomberg reported.

Lilly did not immediately reply to a request for comment from MT Newswires.